We invite you to view the preliminary program for Cytokines 2017, 29 October – 2 November, in Kanazawa, Japan
“Looking beyond the horizon of integrated cytokine, interferon, and chemokine research”
The goal of the meeting is to promote international collaboration and spur new progress in the field of cytokine, interferon, and chemokine research among scientists from industry, academia and regulatory. The meeting will provide an outstanding forum for investigators in basic science and clinical research to present their most recent findings on the role of cytokines (including interferons, chemokines, and various pro-inflammatory/anti-inflammatory factors) in infection, cancer, allergy and autoimmunity, as well as in various other inflammatory and immune diseases. The meeting will also provide an opportunity for updates on the development of novel therapeutic interventions in these fields.
View Preliminary Program
Kanazawa is a beautiful castle town that was spared devastation during the second World War, and the Kanazawa’s rich culture can still be experienced today. Access is via high-speed railway from Tokyo to Kanazawa in 2.5 hours. Participants will enjoy the beauty of the Japanese Alps and the Sea of Japan coastline in their best season, when the autumn leaves are in full color.
The Organizing Committee wishes to thank the following sponsors for their early show of commitment to support Cytokines 2017:
Congress Banquet Sponsor:
Exhibitors & Sponsors:
Very sincerely yours,
Kouji Matsushima (The University of Tokyo), President
Tadamitsu Kishimoto (Osaka University), Honorary President
Yoichiro Iwakura (Tokyo University of Science), Vice President
Takashi Fujita (Kyoto University)
Shuichi Kaneko (Kanazawa University)
Akihiko Yoshimura (Keio University), Program Chair
Naofumi Mukaida (Kanazawa University), Secretary General
ICIS2017 Congress Secretariat
c/o Japan Convention Services, Inc.
Daido Seimei Kasumigaseki Bldg. 14F,
1-4-2 Kasumigaseki, Chiyodaku, Tokyo 100-0013, Japan
TEL：+81 3-3508-1214 FAX : +81 3-3508-1302
E-mail: [email protected]